OTCMKTS:IDRSF Idorsia (IDRSF) Stock Price, News & Analysis $5.38 0.00 (0.00%) As of 10/23/2026 Add Compare Share Share Stock Analysis Stock AnalysisAnalyst ForecastsChartNews and Trends About Idorsia Stock (OTCMKTS:IDRSF) View Price History Chart DataSkip Price History Chart 1 Day 5 Days 30 Days 90 Days 1 Year Advanced 1 Day 1 Day 5 Days 30 Days 90 Days 1 Year Advanced Show volume Show extended hours Get Idorsia alerts:Sign Up Key Stats Today's Range$5.38▼$5.3850-Day Range$5.19▼$7.7552-Week Range$3.50▼$8.19VolumeN/AAverage Volume9,708 shsMarket CapitalizationN/AP/E RatioN/ADividend YieldN/APrice TargetN/AConsensus RatingModerate Buy Company Overview Idorsia Ltd. is a Swiss biopharmaceutical company focused on discovering, developing and commercializing innovative medicines. The company conducts research in areas including central nervous system disorders, cardiovascular disease, immunology and orphan diseases, with the goal of addressing conditions that may have limited treatment options. Idorsia was established in 2017 following the acquisition of Actelion by Johnson & Johnson. The company was formed to continue Actelion’s drug-discovery and development activities outside the acquired business. Idorsia is headquartered in Allschwil, Switzerland, and operates through research, development and commercial activities serving international markets. Its medicines include QUVIVIQ (daridorexant), an orexin receptor antagonist approved in multiple markets for the treatment of insomnia, and products based on its pipeline of internally discovered compounds and external collaborations. Idorsia’s leadership includes co-founder and Chief Executive Officer Jean-Paul Clozel, who previously held a senior scientific and executive role at Actelion.AI Generated. May Contain Errors. Read More Receive IDRSF Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Idorsia and its competitors with MarketBeat's FREE daily newsletter. Submit View SMS TermsSMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. IDRSF Stock News HeadlinesIdorsia Enrolls First Patients in Study to Add Daytime Benefits to Insomnia Drug's Label2 hours ago | marketscreener.comMIdorsia Plans Autism Program for Insomnia Drug DaridorexantOctober 26 at 7:15 AM | marketscreener.comMWould Anthropic IPO Burst the Bubble?The biggest IPO in history is likely just weeks away… Anthropic, the company behind Claude AI, is rumoured to be lining up a Nasdaq debut before Thanksgiving… at a valuation of up to $2 trillion. But here’s what nobody’s talking about… A raise of about $100 billion doesn’t just make headlines. It puts an enormous spotlight on the AI industry. And as investors rush to find the next big opportunity in artificial intelligence, some of the most interesting plays may be hiding outside traditional AI stocks.October 27 at 1:00 AM | Crypto 101 Media (Ad)Idorsia Ltd Presents Phase 2 Results With Daridorexant In Children With Insomnia Disorder And Adult Evidence At Sleep Europe 2026October 24 at 7:05 AM | marketscreener.comMIdorsia presents outstanding results with daridorexant in children and adolescents with insomnia and an expanding body of evidence in adults at Sleep Europe 2026October 24 at 1:48 AM | marketscreener.comMIdorsia (IDRSF) Expected to Release Earnings on ThursdayOctober 22, 2026 | americanbankingnews.comIdorsia Ltd Shares Positive Findings from Two New Analyses of the Pivotal Phase 3 Precision Study of Aprocitentan in Patients with Resistant HypertensionOctober 12, 2026 | marketscreener.comMIdorsia Ltd Announces New Results Across Pediatric, Adult and Real-World Insomnia Settings Highlight the Expanding Clinical Evidence for Daridorexant At Sleep Europe 2026October 9, 2026 | marketscreener.comMSee More Headlines IDRSF Stock Analysis - Frequently Asked Questions How have IDRSF shares performed this year? Idorsia's stock was trading at $5.25 on January 1st, 2026. Since then, IDRSF shares have increased by 2.5% and is now trading at $5.38. How do I buy shares of Idorsia? Shares of IDRSF stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. What other stocks do shareholders of Idorsia own? Based on aggregate information from My MarketBeat watchlists, some other companies that Idorsia investors own include Lakefront Biotherapeutics American Depositary Shares (LKFT), Moderna (MRNA), Tesla (TSLA), Workhorse Group (WKHS), Transocean (RIG), Air Canada (AC) and adidas (ADS). Company Calendar Today10/27/2026Next Earnings (Estimated)10/29/2026Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeOTCMKTS SectorHealthcare Industry Biotechnology Sub-IndustryBiotechnology Current SymbolOTCMKTS:IDRSF CIKN/A Webwww.idorsia.com Phone(158) 844-0000FaxN/AEmployees487Year FoundedN/AProfitability EPS (Trailing Twelve Months)N/A Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet IncomeN/A Net MarginsN/A Pretax MarginN/A Return on EquityN/A Return on AssetsN/A Debt Debt-to-Equity RatioN/A Current RatioN/A Quick RatioN/A Sales & Book Value Annual SalesN/A Price / SalesN/A Cash FlowN/A Price / Cash FlowN/A Book ValueN/A Price / BookN/AMiscellaneous Outstanding SharesN/AFree FloatN/AMarket CapN/A OptionableNot Optionable BetaN/A 10 Best Stocks to Own in Fall 2026AI spending is reshaping the market, and the opportunity extends far beyond the biggest chipmakers. Discover 10 stocks set to benefit from powerful trends in AI infrastructure, cloud computing, energy, capital returns, and consumer growth this fall.Get This Free Report This page (OTCMKTS:IDRSF) was last updated on 10/23/2026 by MarketBeat.com Staff. From Our Partners80 Days Until America's Rare Earth Supply Chain ShiftChina controls more than 90% of global rare earth alloy production, leverage it is using to restrict exports t...The Tomorrow Investor | SponsoredTwo charts tell you the future…Gold miners are posting record cash flows, outperforming every other sector, yet mining still makes up just 1%...Golden Portfolio | SponsoredWould Anthropic IPO Burst the Bubble?The biggest IPO in history is likely just weeks away… Anthropic, the company behind Claude AI, is rumoured ...Crypto 101 Media | SponsoredThe investigation Porter spent tens of thousands to documentPorter Stansberry flew the Porter and Co. team 3,300 miles to Dublin to investigate a 17-year investing experi...Porter & Company | SponsoredHe turned $12K into $1.65M without touching Apple or TeslaTim Sykes turned $12,415 in gift money into more than $1.65 million before graduating college, without trading...Tim Sykes | SponsoredLast call for your free 0DTE reportThe 0DTE Game Plan lays out a simple 3-step framework for trading same-day options: Plan it, profit from it, p...Profits Run | SponsoredWhy Gerardo Del Real says wait before buying uranium stocksGerardo Del Real is calling it the Third Convergence Event, a new catalyst hitting the uranium market that he ...Digest Publishing | SponsoredElon Musk’s Hushed FCC Filing. Dec 8th.Elon Musk quietly filed a document with the federal government tied to artificial intelligence, one of the lar...Paradigm Press | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Idorsia Ltd Please log in to your account or sign up in order to add this asset to your watchlist. Share Idorsia With A Colleague Link copied to clipboard. Unlock superior investment research and tools. Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools and reports. Get MarketBeat All Access MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
